期刊文献+

环丝氨酸治疗耐药结核菌患者的效果观察 被引量:2

Effect of cycloserine on the patients underwent drugs resistant bacillus tuberculosis
下载PDF
导出
摘要 目的:观察环丝氨酸治疗耐药结核菌患者的效果。方法:选择100例耐药结核病患者,随机分为两组:环丝氨酸组和对氨基水杨酸组,分别应用环丝氨酸和对氨基水杨酸。记录两组治疗后3个月、6个月、12个月、24个月痰菌阴转的患者例数,记录两组治疗结束时X线胸片病灶吸收情况,记录两组患者的不良反应。结果:治疗后两组患者在各个阶段的阴转率比较差异均无统计学意义(P>0.05)。病灶吸收率两组比较差异无统计学意义(P>0.05)。环丝氨酸组患者的肝功能损伤发生率明显低于对氨基水杨酸组患者(P<0.05),其他不良反应两组患者发生率比较,差异无统计学意义(P>0.05)。结论:环丝氨酸治疗耐药结核菌患者的效果良好,不良反应少。 Objective To observe the effect of cyclosefine on the patients underwent drugs resistant bacillus tuberculosis. Method One hundred patients underwent drugs resistant bacillus tuberculosis were divided into two groups: eycloserine group and p - aminosalicylic acid group. The patients in beth groups were administrated with cycloserine and p - aminosalicylic acid respectively. The number of sputum nega- tive conversion after 3 months ,6 months, 12 months,24 months of treatment were recorded in both groups. The X - ray chest radiograph le- sions absorption and complication in both groups were recorded. Results There were no significant difference in sputum negative conversion and X - ray chest radiograph lesions absorption( P 〉 0. 05 ). The incidence of liver damage in cycloserine group was lower than it in p - aminosalicylie acid group (P 〈 0. 05 ) . Other complication were not significantly different between two groups (P 〉 0. 05 ). Conclusion Cycloserine is effect for the patients underwent drugs resistant bacillus tuberculosis and its complication are few.
出处 《吉林医学》 CAS 2014年第4期697-698,共2页 Jilin Medical Journal
关键词 耐药结核菌 环丝氨酸 对氨基水杨酸 Drugs resistant bacillus tubereulosis Cycloserine P- aminosalicylie acid
  • 相关文献

参考文献7

  • 1陈永忠,潘洪秋.利福布汀联用罗红霉素对耐多药结核患者的疗效观察[J].临床医学工程,2012,19(10):1716-1718. 被引量:6
  • 2谢安,肖和平.环丝氨酸在治疗耐多药结核病方面的应用[J].中华结核和呼吸杂志,2012,35(12):949-950. 被引量:20
  • 3马屿.耐多药结核病及其防治[J].临床肺科杂志,2005,10(2):137-140. 被引量:118
  • 4Goble M,Iseman MD,Madsen LA. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin[J].{H}New England Journal of Medicine,1993,(8):527.
  • 5Bruning JB,Murillo AC,Chacon O. Structure of the Mycobacterium tuberculosis D-alanine:D-alanine ligase,a target of the antituberculosis drug D-cycloserine[J].{H}Antimicrobial Agents and Chemotherapy,2011,(1):291.
  • 6Falzon D,Jaramillo E,Schünemann HJ. WHO guidelines for the programmatic management of drug-resistant tuberculosis:2011 update[J].{H}European Respiratory Journal,2011,(3):516.
  • 7World Health Organization. Management of MDR-TB:a field guide-a companion document to guidelines for the programmatic management of drug-resistant tuberculosis[M].{H}Geneva:World Health Organization,2008.20.

二级参考文献25

  • 1张侠,李敏,胡春梅,于俊,林霏申,茅惠娟,张向荣,吴玉君.利福布汀治疗耐多药肺结核临床观察[J].中国抗生素杂志,2006,31(4):223-224. 被引量:13
  • 2结核病诊断细菌学检验规程[J].中国防痨杂志,1996,18(1):28-31. 被引量:799
  • 3中华医学会结核病科学会.肺结核化学疗法[J].中华结核和呼吸系疾病杂志,1982,6:381-385.
  • 4姚艳红,张鲁予,田红,王翠琴.罗红霉素辅助治疗复治肺结核疗效观察[J].临床肺科杂志,2007,12(11):1194-1196. 被引量:1
  • 5Johnson BJ, Estrada I, Shen Z, et ol. Differential gene expression in response to adjunctive recombinant human interleukin-2 immunothera- py in multidrug-resistant tuberculosis patients [ J] . Infect Immun, 1998, 66 (6) : 2426-2433.
  • 6Parnham MJ. Immunomodulatory effects of antimicrobials in the thera- py of respiratory tract infection [J] . Curr opin Infect Dis, 2005, 18 (2) : 125-131.
  • 7Falzon D, Jaramillo E, Schtinemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J, 2011, 38: 516-528.
  • 8Conde MB, Melo FA, Marques AM, et al. III Brazilian Thoracic Association Guidelines on tuberculosis. J Bras Pneumol, 2009, 35 : 1018-1048.
  • 9Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/ Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med, 2003, 167 : 603-662.
  • 10Handbook of anti-tuberculosis agents. Introduction. Tuberculosis (Edinb) , 2008, 88 : 85-86.

共引文献140

同被引文献25

  • 1唐神结,肖和平.结核病内科治疗的现状与展望[J].结核病与肺部健康杂志,2012,1(1). 被引量:5
  • 2Falzon D, Jaramillo E, Schilnemann HJ, et al. WHO guidelinesfor the programmatic management of drug-resistant tuberculosis:2011update[J]. Eur Respir J,2011,38:516-528.
  • 3中国全球基金结核病项目(一期)实施细则治疗药物[Z].中国全球基金结核病项目办公室,2010,11.
  • 4中国全球基金结核病项目(一期)实施细则治疗方案[Z].中国全球基金结核病项目办公室,2010, 11.
  • 5Prasad R, Verma SK, Sahai S, et al. Efficacy and safety of kanarnycin, ethionamide, PAS and cycloserine in multidrugre-sistant pulmonary tuberculosis patients[J]. Indian J Chest Dis ALlied Sci, 2006, 48 (3): 183-186.
  • 6Tahaoglu K, Torun T, Sevim T, et al. The treatment of multidrug-resistant tuberculosis in TurkeyCj]. N Engl j Med, 2001,345(3):170-174.
  • 7Masjedi MR, Tabarsi P, Chitsaz E, et al. Outcome of treatmentof MDR-TB patients with standardised regimens, Iran. 2002-2006[J]. Int J Tuberc Lung Dis, 2008,12(7):750-755.
  • 8中国全球基金结核病项目(一期)实施细则广泛耐药肺结核标准化治疗方案[Z].中国全球基金结核病项目办公室,2010,11.
  • 9中国全球基金结核病项目(一期)实施细则耐多药肺结核标准化治疗方案[Z].中国全球基金结核病项目办公室,2010, 11.
  • 10中国全球基金结核病项目(一期)实施细则药物替代[Z].中国全球基金结核病项目办公室,2010, 11.

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部